troglitazone has been researched along with Ureteral Obstruction in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we investigated the anti-fibrotic and anti-inflammatory effects of the TZD troglitazone in the mouse model of unilateral ureteral obstruction (UUO)." | 3.75 | PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. ( Arakawa, T; Doi, S; Doi, T; Kawai, T; Kohno, N; Masaki, T; Yokoyama, Y; Yorioka, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawai, T | 1 |
| Masaki, T | 1 |
| Doi, S | 1 |
| Arakawa, T | 1 |
| Yokoyama, Y | 1 |
| Doi, T | 1 |
| Kohno, N | 1 |
| Yorioka, N | 1 |
1 other study available for troglitazone and Ureteral Obstruction
| Article | Year |
|---|---|
PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.
Topics: Actins; Animals; Anti-Inflammatory Agents; Arterioles; Blood Glucose; Cell Proliferation; Chromans; | 2009 |